IPPOSI (@ipposi) 's Twitter Profile
IPPOSI

@ipposi

IPPOSI puts patient voices at the centre of healthcare & policy. Irish Platform for Patient Organisations, Science & Industry.
Registered Charity: RCN: 20062934

ID: 945982350

linkhttp://www.ipposi.ie calendar_today13-11-2012 15:30:12

4,4K Tweet

4,4K Followers

1,1K Following

EUPATI (@eupatients) 's Twitter Profile Photo

Exciting Announcement! 🚀 We are thrilled to share that the new EU Health Technology Assessment Regulation course is now live on EUPATI Open Classroom!: bit.ly/3x4Am6N This course is a major milestone in preparing patients for the new #EUHTAR process starting in 2025.🌟

Exciting Announcement! 🚀
We are thrilled to share that the new EU Health Technology Assessment Regulation course is now live on EUPATI Open Classroom!: bit.ly/3x4Am6N
This course is a major milestone in preparing patients for the new #EUHTAR process starting in 2025.🌟
HPRA (@thehpra) 's Twitter Profile Photo

We were delighted this week to host the second Patient Forum meeting of the year. The forum was established to provide a platform for dialogue between the HPRA and patients/patient representatives to ensure their voices are heard and incorporated into the regulation of medicines

We were delighted this week to host the second Patient Forum meeting of the year. The forum was established to provide a platform for dialogue between the HPRA and patients/patient representatives to ensure their voices are heard and incorporated into the regulation of medicines
WLR (@wlrfm) 's Twitter Profile Photo

🎙️ #TheHotDesk with #MKBrazil 🚢 Dawn Meats secured a contract with a leading South Korean company. 🤖 AI in healthcare? The public has a say thanks to IPPOSI 🏃‍♀️We hear from staff at Dgfoods & MEDITE SMARTPLY who are sponsors of Waterford Viking Marathon 📲 wlrfm.com

IPPOSI (@ipposi) 's Twitter Profile Photo

Thanks to Irish Medical Times 🇺🇦 for helping to spread the word. Why not join the Citizens' Jury to discuss AI in Healthcare? bit.ly/juryform1 #citizensjuryAI imt.ie/opinion/commen…

IPPOSI (@ipposi) 's Twitter Profile Photo

Have your say on the future of AI in Healthcare by joining the Citizens' Jury here bit.ly/juryform1 No previous knowledge of the topic is required. #citizensjuryAI

Have your say on the future of AI in Healthcare by joining the Citizens' Jury here bit.ly/juryform1 No previous knowledge of the topic is required. #citizensjuryAI
IPPOSI (@ipposi) 's Twitter Profile Photo

Application closing date for Citizens' Jury on AI in Healthcare is June 21st. Please apply here bit.ly/juryform1 No previous knowledge of the topic is required. Further information available at ipposi.ie/aicitizensjury/ #citizensjuryAI Thank you to all applicants to date.

Application closing date for Citizens' Jury on AI in Healthcare is June 21st. Please apply here bit.ly/juryform1 No previous knowledge of the topic is required. Further information available  at ipposi.ie/aicitizensjury/ #citizensjuryAI Thank you to all applicants to date.
IPPOSI (@ipposi) 's Twitter Profile Photo

Interested in helping shape the future of AI in Healthcare? Apply to serve on the Citizens' Jury bit.ly/juryform1 Applications welcome from residents 18+ years. Closing date Friday June 21st NYCI Foróige Youth Work Ireland The Wheel Young Social Innovators Comhairle na nÓg #citizensjuryAI

Interested in helping shape the future of AI in Healthcare? Apply to serve on the Citizens' Jury bit.ly/juryform1 Applications welcome from residents 18+ years. Closing date Friday June 21st
<a href="/nycinews/">NYCI</a> <a href="/Foroige/">Foróige</a> <a href="/ywirl/">Youth Work Ireland</a> <a href="/The_Wheel_IRL/">The Wheel</a> <a href="/YSInow/">Young Social Innovators</a>
 <a href="/ComhairleNaNog1/">Comhairle na nÓg</a> #citizensjuryAI
IPPOSI (@ipposi) 's Twitter Profile Photo

Thank you to all our 500+ Citizens' Jury applicants. We are delighted with the level of interest expressed and look forward to being in touch with applicants shortly. Applicants who have not heard from us by Monday, July 1st, please check your Spam folder or contact us directly.

Thank you to all our 500+ Citizens' Jury applicants. We are delighted with the level of interest expressed and look forward to being in touch with applicants shortly. Applicants who have not heard from us by Monday, July 1st, please check your Spam folder or contact us directly.
NCPE (@info_ncpe) 's Twitter Profile Photo

The NCPE are seeking input from Patient Organisations for our appraisal of Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. For more details see:ncpe.ie/for-patients

The NCPE are seeking input from Patient Organisations for our appraisal of Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. For more details see:ncpe.ie/for-patients
IPPOSI (@ipposi) 's Twitter Profile Photo

As part of implementing the EU Health Data Space, HIQA Department of Health HSE Ireland HealthResearchBoard are creating a Public/Patient Involvement Panel on “Collecting, using, sharing health information for better services, policy, research & innovation” Details here: bit.ly/3yq176B

As part of implementing the EU Health Data Space, <a href="/HIQA/">HIQA</a> <a href="/roinnslainte/">Department of Health</a> <a href="/HSELive/">HSE Ireland</a> <a href="/hrbireland/">HealthResearchBoard</a> are creating a Public/Patient Involvement Panel on “Collecting, using, sharing health information for better services, policy, research &amp; innovation” Details here:  bit.ly/3yq176B
NCPE (@info_ncpe) 's Twitter Profile Photo

The NCPE are seeking input from Patient Organisations for our appraisal of Pembrolizumab (Keytruda) in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic HER2-negative gastric..(1/2)

The NCPE are seeking input from Patient Organisations for our appraisal of Pembrolizumab (Keytruda) in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic HER2-negative gastric..(1/2)
Children's Health Ireland (@chi_ireland) 's Twitter Profile Photo

Excited to announce the launch of the new national YPAG with @In4Kids. CHI & In4kids believe children and young people should have a voice and be actively involved in design and delivery of clinical research and trials. Check out the poster below for more info.

Excited to announce the launch of the new national YPAG with @In4Kids. 

CHI &amp; In4kids believe children and young people should have a voice and be actively involved in design and delivery of clinical research and trials. 

Check out the poster below for more info.
IPPOSI (@ipposi) 's Twitter Profile Photo

We are pleased to present our 2025 pre-budget submission calling for greater investment in digital health solutions; public and patient partnership; and access to medicines and innovation. What would you like to see included in the 2025 budget?bit.ly/4cw6iQb

We are pleased to present our 2025 pre-budget submission calling for greater investment in digital health solutions; public and patient partnership; and access to medicines and innovation. What would you like to see included in the 2025 budget?bit.ly/4cw6iQb
NCPE (@info_ncpe) 's Twitter Profile Photo

The NCPE are seeking input from Patient Organisations for our appraisal of zanubrutinib (Brukinsa) monotherapy for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. More details at  (ncpe.ie/for-patients)

The NCPE are seeking input from Patient Organisations for our appraisal of zanubrutinib (Brukinsa) monotherapy for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. More details at  (ncpe.ie/for-patients)
NCPE (@info_ncpe) 's Twitter Profile Photo

The NCPE are seeking input from Patient Organisations for our appraisal of dostarlimab (Jemperli) in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient microsatellite instability-high (1/2)

The NCPE are seeking input from Patient Organisations for our appraisal of dostarlimab (Jemperli) in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient microsatellite instability-high (1/2)
IPPOSI (@ipposi) 's Twitter Profile Photo

Anyone with an interest in our previous #Citizens #juries can view the outputs on our website - ipposi.ie/services/citiz…. Our 2024 jury is on the topic of #ArtificialInteligence in #healthcare . ipposi.ie/aicitizensjury/